All In MedTech

Device Trial Radar · NCT06056154

Safety and Efficacy of the Hydrophobic Intraocular Lens Asqelio Monofocal With Biaspheric Design

Last checked: Nov 20, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 17, 2024

Primary completion

May 2025

Study completion Jul 2025

Sponsor

Lead sponsor
AST Products, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Sep 28, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this observational study is to learn about the Asqelio monofocal intraocular lens (IOL) model QLIO130C in patients undergoing cataract surgery. The aim of the study is to evaluate the lens implementation safety and efficacy after at least 24 months.

Conditions

  • Cataract
  • Pseudophakia

Interventions

  • LIO ASQELIO TM monofocal QLIO130CDevice

    Intraocular lens (IOL) implant. All patients will have been treated as per standard clinical practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Posterior capsular opacityTime frame: 24 months after IOL implantation

2 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Oftalmología Vistahermosa SL

    Alicante, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.